Systemic therapy for central nervous system metastases

Exploiting cancer stress for new therapies

NeoALTTO trial results

Zoledronic acid disappointment for early breast cancer

Next generation gene sequencing

Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer

CTCs predict poor outcome from blood stem cell transplantation therapy for metastatic breast cancer

Denosumab delayed first skeletal-related side effect

High CTC levels predicted poor outcome in metastatic breast cancer

CTCs predicted recurrence and death in patients with early-stage breast cancer

Combination therapy reduced HER2-positive breast cancers

Neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer